Trial Profile
A study evaluating safety and efficacy of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir/dasabuvir regimens in persons with chronic kidney disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Oct 2017
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 23 Oct 2017 New trial record
- 08 Oct 2017 Results presented at the IDWeek 2017